Deflazacort's Effect on Coagulation Pathways

Understanding PT/INR Testing

PT/INR testing evaluates the extrinsic and common coagulation pathways, including factors II, V, VII, X, and fibrinogen 1
The INR was designed and validated to assess coagulation status only in patients receiving vitamin K antagonist therapy, not as a general predictor of bleeding risk 2
INR is calculated using the patient's PT, mean normal PT, and the international sensitivity index (ISI) of the thromboplastin reagent according to the formula: INR = [PTpatient/PTnormal]^ISI 3

PT/INR values are primarily affected by vitamin K antagonist therapy (warfarin) 4
Liver dysfunction affecting synthesis of clotting factors can impact PT/INR values 4
Consumption of coagulation factors (e.g., DIC) can affect PT/INR results 1
Lupus anticoagulant can impact PT/INR values in some cases 3

The therapeutic INR range is typically 2.0-3.0 (target 2.5) for patients on vitamin K antagonists (VKA) 4
Medications that don't directly affect coagulation factors (like deflazacort) would not be expected to alter PT/INR values 2
For patients with liver disease, standard INR may not be appropriate and could require a modified INR calculation 4

Long-term corticosteroid use may indirectly affect coagulation through other mechanisms (e.g., potential effects on liver function in some patients) 4
The INR scale is only validated for patients on VKA with no other superimposed coagulation defects 4
For accurate PT/INR interpretation, consider the clinical context (whether patient is on anticoagulants, has liver disease, etc.) 2

The American College of Cardiology notes that genetic variations in CYP2C9 and VKORC1 enzymes affect warfarin metabolism in patients on vitamin K antagonists 5

Liver disease with impaired synthesis of procoagulant factors (I, II, V, VII, X) can cause an elevated PT/INR, as indicated by Gastroenterology research 6, 7
The American College of Cardiology suggests that lupus anticoagulant can also cause an elevated PT/INR, although this typically causes only slight PT prolongation 5

The American College of Cardiology recommends that thromboplastin reagent variability, incorrect citrate concentration, underfilled collection tubes, automated clot detection methods, and incorrect mean normal PT determination can artificially derange PT/INR results 5

The European Heart Journal states that the therapeutic INR range of 2.0-3.0 applies only to patients on vitamin K antagonists for conditions like atrial fibrillation 8, 5
The Journal of Thrombosis and Haemostasis indicates that there is no high-quality evidence supporting treatment of INRs below 2.0 in patients not receiving warfarin therapy 9, 10

The Journal of Thrombosis and Haemostasis advises against using PT/INR as a general screening test for coagulopathy or to predict procedural bleeding risk in non-warfarin patients, as it lacks validity for these purposes and can lead to unnecessary plasma transfusions 9, 10, 6